Who are Group S+T's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): fingolimob (FTY), FTY720, TDT067, Centhaquine + Standard Treatment, SAIT101, RO0503821 (1x/4 Weeks).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/group-s-t.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Group S+T — Competitive Intelligence Brief

Group S+T (Group S+T) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: S1P receptor modulator. Area: Immunology.

marketed S1P receptor modulator S1P1 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Group S+T (Group S+T) — Huazhong University of Science and Technology. This drug targets the S1P receptor to modulate lymphocyte trafficking and reduce inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Group S+T TARGET	Group S+T	Huazhong University of Science and Technology	marketed	S1P receptor modulator	S1P1
fingolimob (FTY)	fingolimob (FTY)	University Hospital, Clermont-Ferrand	marketed	Sphingosine-1-phosphate receptor modulator	S1P1 receptor (sphingosine-1-phosphate receptor 1)
FTY720	FTY720	Novartis Pharmaceuticals	marketed	Sphingosine-1-phosphate receptor modulator; Immunomodulator	Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)
TDT067	TDT067	Celtic Pharma Development Services	phase 3	S1P1 receptor modulator	S1P1
Centhaquine + Standard Treatment	Centhaquine + Standard Treatment	Pharmazz, Inc.	phase 3	S1P receptor agonist	Sphingosine-1-phosphate receptor 1 (S1P1)
SAIT101	SAIT101	Archigen Biotech Limited	phase 3	S1P1 receptor modulator	S1P1
RO0503821 (1x/4 Weeks)	RO0503821 (1x/4 Weeks)	Hoffmann-La Roche	phase 3	S1P receptor modulator	S1P1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (S1P receptor modulator class)

Promius Pharma, LLC · 2 drugs in this class
Nobelpharma · 2 drugs in this class
Bausch & Lomb Incorporated · 1 drug in this class
Biogen · 1 drug in this class
Celgene · 1 drug in this class
Geropharm · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Huazhong University of Science and Technology · 1 drug in this class
Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Group S+T — Competitive Intelligence Brief. https://druglandscape.com/ci/group-s-t. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab